Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
270.19
+19.04 (7.58%)
At close: May 12, 2025, 4:00 PM
272.00
+1.81 (0.67%)
After-hours: May 12, 2025, 6:48 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 24 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 324.54, with a low estimate of 220 and a high estimate of 500. The average target predicts an increase of 20.12% from the current stock price of 270.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock from 25 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 11 | 11 | 12 |
| Buy | 7 | 8 | 8 | 9 | 9 | 9 |
| Hold | 5 | 5 | 4 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 23 | 24 | 24 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $331 → $349 | Strong Buy | Maintains | $331 → $349 | +29.17% | May 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $300 → $325 | Strong Buy | Maintains | $300 → $325 | +20.29% | May 2, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $284 → $268 | Hold | Maintains | $284 → $268 | -0.81% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $320 | Strong Buy | Reiterates | $320 | +18.44% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $500 | Strong Buy | Reiterates | $500 | +85.05% | Apr 2, 2025 |
Financial Forecast
Revenue This Year
2.97B
from 2.25B
Increased by 31.93%
Revenue Next Year
3.83B
from 2.97B
Increased by 29.20%
EPS This Year
-1.76
from -2.18
EPS Next Year
0.75
from -1.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6B | 5.9B | 6.9B | ||
| Avg | 3.0B | 3.8B | 4.9B | ||
| Low | 2.7B | 3.0B | 3.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 62.2% | 99.0% | 81.2% | ||
| Avg | 31.9% | 29.2% | 28.3% | ||
| Low | 18.1% | 2.4% | -1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.13 | 5.02 | 12.39 | ||
| Avg | -1.76 | 0.75 | 5.77 | ||
| Low | -3.59 | -2.43 | 2.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,558.7% | ||
| Avg | - | - | 671.9% | ||
| Low | - | - | 222.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.